J
Jnana
A clinical-stage biotechnology company leveraging its next-generation chemoproteomics RAPID platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high…
About Jnana
Jnana Therapeutics is a biotechnology startup that operates in the pharmaceutical industry. The company focuses on the discovery and development of new drugs using a next-generation chemoproteomics platform, known as the RAPID platform. This platform allows Jnana to create small molecule medicines at a faster and more efficient rate than traditional methods.
The company's primary target market is patients in need of new treatments for various diseases. Jnana is currently working on first- and best-in-class therapies for phenylketonuria (PKU), a rare genetic disorder, as well as a wide range of immune-mediated diseases and cancers.
Jnana's business model revolves around the development of these new drugs and therapies. Once a drug is developed and approved, it can be sold to healthcare providers and patients. The company also explores partnerships to expand its reach and capabilities.
In addition to its drug development efforts, Jnana also participates in healthcare and investor conferences to present its progress and attract potential investors. The company also offers opportunities for professionals to join their team and contribute to their mission of advancing drug discovery.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Boston, United States
- Employees
- 92
- Open positions
- 3
- Dealroom signal
- 72.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Aug 2024 | $800M | — | Otsuka Pharmaceutical | ↗ |
| SERIES COther financing | Nov 2022 | $107M | $428M | RA Capital Management · Pfizer Venture Investments · Bain Capital Life Sciences · Polaris Partners | ↗ |
Growth signals
Latest recorded traffic for Jnana is 7.5K monthly website visits, up 87.5% over the last three months. Jnana's team declined 2.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Polaris Partners
Versant Ventures
Avalon Ventures
Abbvie Biotech Ventures
RA Capital Management- PIPfizer Venture Investments
Series B and later1 investor entered at this stage
Bain Capital Life Sciences
Other known investors1 additional known investor
Otsuka Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jnana on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jnana’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.